Manulife completes $3.2 billion long term care reinsurance with Munich Re, moving risk off its balance sheet

Manulife moves long term care risk to Munich Re in USD 3.2 billion transaction

Manulife Financial Corporation has closed a reinsurance transaction that transfers the biometric risk on a block of its long term care policies, representing about USD 3.2 billion of reserves, to Munich American Reassurance Company, a United States life reinsurance subsidiary of Munich Re Group. The deal, announced by Manulife and reported by reinsurance industry press, is intended to reduce the insurer’s exposure to long term care morbidity while having a limited near term impact on earnings and capital.

Structure and immediate impact

According to company disclosures and industry reporting, the transaction is a standalone long term care cession that does not include asset transfers. Manulife described the arrangement as largely capital neutral and said the first year effect on core earnings and on net income attributable to shareholders is immaterial, roughly USD 30 million, and is expected to decline in later years. The company also said the transaction follows the pricing patterns of its prior long term care reinsurance deals and includes a modest negative 5 percent cede, which management said reinforces the validity of its reserves and actuarial assumptions.

Why the deal matters for Manulife and the market

Long term care liabilities have been a focus for life insurers globally as populations age and claims patterns evolve. For Manulife, this is its third long term care reinsurance operation in recent years and the first that is structured as a standalone long term care block. By shifting biometric risk to Munich Re Life US, Manulife reduces its cumulative sensitivity to long term care morbidity, a move that lowers earnings volatility tied to care cost and claim incidence assumptions.

From a market perspective, reinsurance transactions of this scale underline how primary insurers and global reinsurers are managing longevity and morbidity exposures. For reinsurers, long term care business provides a way to diversify portfolios and pick up long dated cash flows aligned with their capital and risk appetite. For primary insurers, these deals free up management bandwidth and capital to focus on core growth initiatives and new product development.

Broader context and previous transactions

Manulife has pursued similar risk transfer strategies in recent years, including multi billion dollar deals that reallocated blocks of life and long term care business to third party reinsurers. Those prior transactions have been presented by the company as tools to reduce risk concentrations and to release regulatory capital for shareholder returns or strategic reinvestment. The company said the new Munich Re arrangement complements that prior activity and contributes to an overall objective of lowering sensitivity to long term care morbidity by around 24 percent cumulatively when combined with earlier transactions.

What this means for policyholders and investors

The transaction is a risk transfer between two well established financial institutions and does not change policy benefits for the covered policyholders. Manulife and the reinsurer typically continue to be subject to relevant regulatory oversight in the jurisdictions where the policies were issued, and policy terms remain in force under the existing contractual framework. For investors, the deal is intended to make Manulife’s earnings profile more predictable and reduce the risk of unexpected reserve strain from adverse morbidity experience in the long term care block.

Industry reaction and next steps

Industry commentary highlights that large scale long term care transactions remain a practical option for life insurers seeking to manage demographic risk. Reinsurers that have the capacity to assume long dated biometric risk see these deals as opportunities to deploy capital into diversified, long duration liabilities. Market participants will monitor how pricing, structure, and the appetite for similar deals evolve, as that will influence how much more of long term care risk is shifted out of primary insurers over the coming quarters.

Manulife noted the transaction is now in force. The company referenced its August announcement that first outlined the agreement. Manulife continues to publish periodic financial disclosures that will reflect the transaction in future reporting and regulatory filings.

Why this matters now: insurers globally are balancing the competing pressures of demographic shifts, rising care costs, and regulatory capital requirements. Large reinsurance agreements like this one represent a pragmatic tool that changes the distribution of long term care liability across the financial sector, while aiming to preserve benefit security for existing policyholders and reduce earnings volatility for shareholders.